Durvalumab with stereotactic body radiation therapy for treating unresected stage I/II non-small-cell lung cancer

Durvalumab with stereotactic body radiation therapy is currently in development for the treatment of unresected stage I/II non-small cell lung cancer in adults aged 18 years and older.
Lung cancer is one of the most common and serious types of cancer, affecting more than 43,000 people every year in the UK, and 52% of the cases occur in males. Non-small cell lung cancer is
the most common form of lung cancer, accounting for around 80 to 85 out of 100 cases. Stage I/II non-small cell lung cancer is an early-stage non-small cell lung cancer, while an unresected
(unresectable) stage I/II non-small cell lung cancer is an early-stage non-small cell lung cancer that cannot be removed through surgery. The most common symptoms of lung cancer are having a
new cough or a cough most of the time, getting out of breath doing the things you used to do without a problem, coughing up phlegm (sputum) with blood in it, and having aches or pain in the
chest or shoulder. The biggest cause of lung cancer in the UK is tobacco smoking. However, other risk factors increase the risk of developing lung cancer such as exposure to asbestos, silica, radon gas and diesel engine exhaust fumes, and a family history of lung cancer. Although safe, the standard treatment for unresected stage I/II still records failures that increase with tumour size, hence, more effective treatment options are needed.